Intranasal topical estrogen in the management of epistaxis in hereditary hemorrhagic telangiectasia

被引:12
作者
Minami, Kazuhiko [1 ]
Haji, Tomoyuki [2 ]
机构
[1] Saitama Med Univ, Int Med Ctr, Dept Head & Neck Surg, Hidaka, Saitama 3501298, Japan
[2] Prefectural Univ Hiroshima, Fac Hlth & Welf, Dept Commun Sci & Disorders, Mihara, Hiroshima, Japan
关键词
epistaxis severity score; Hereditary hemorrhagic telangiectasia; topical estrogen; hormonal therapy; ARGON PLASMA COAGULATION; CLINICAL-TRIAL; NASAL-MUCOSA; THERAPY; POPULATION; ESTRIOL;
D O I
10.3109/00016489.2015.1129070
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Conclusion Application of topical estriol ointment is an effective treatment for hereditary hemorrhagic telangiectasia (HHT) epistaxis. Objective HHT is an autosomal-dominant disease characterized by epistaxis in more than 96% of patients. Management of this major symptom, epistaxis, has not been standardized. This study reports experience with topical application of estriol in patients with HHT. Methods Five patients with a confirmed diagnosis of HHT who first visited the hospital between 2012 and 2013 received 0.1% estriol ointment and were guided to apply the ointment twice daily to the anterior part of both nasal cavities. Severity of epistaxis was valued using epistaxis severity score (ESS) before and 3 months after initiating therapy. Results Five patients (three males, two females) received treatment. After the initiation of treatment, intensity and frequency of epistaxis became moderate in all patients. ESS decreased significantly from pre- to post-treatment (p = 0.043). No adverse events were recorded during follow-up.
引用
收藏
页码:528 / 531
页数:4
相关论文
共 22 条
[1]   Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells [J].
Albinana, Virginia ;
Bernabeu-Herrero, Maria E. ;
Zarrabeitia, Roberto ;
Bernabeu, Carmelo ;
Botella, Luisa M. .
THROMBOSIS AND HAEMOSTASIS, 2010, 103 (03) :525-534
[2]   Argon plasma coagulation for the treatment of hereditary hemorrhagic telangiectasia [J].
Bergler, W ;
Riedel, F ;
Baker-Schreyer, A ;
Juncker, C ;
Hörmann, K .
LARYNGOSCOPE, 1999, 109 (01) :15-20
[3]   Topical estrogens combined with argon plasma coagulation in the management of epistaxis in hereditary hemorrhagic telangiectasia [J].
Bergler, W ;
Sadick, H ;
Riedel, F ;
Götte, K ;
Hörmann, K .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 2002, 111 (03) :222-228
[4]   Hereditary hemorrhagic telangiectasias:: a challenge for the clinician [J].
Bergler, W ;
Götte, K .
EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 1999, 256 (01) :10-15
[5]   INFLUENCES OF PERCUTANEOUS ADMINISTRATION OF ESTRADIOL AND PROGESTERONE ON HUMAN BREAST EPITHELIAL-CELL CYCLE IN-VIVO [J].
CHANG, KJ ;
LEE, TTY ;
LINARESCRUZ, G ;
FOURNIER, S ;
DELIGNIERES, B .
FERTILITY AND STERILITY, 1995, 63 (04) :785-791
[6]  
Cignarella A, 2001, MED RES REV, V21, P171, DOI 10.1002/1098-1128(200103)21:2<171::AID-MED1005>3.0.CO
[7]  
2-4
[8]   Quality of life in patients with hereditary hemorrhagic telangiectasia in Norway: A population based study [J].
Geirdal, Amy Ostertun ;
Dheyauldeen, Sinan ;
Bachmann-Harildstad, Gregor ;
Heimdal, Ketil .
AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2012, 158A (06) :1269-1278
[9]  
HARRISON DFN, 1982, LARYNGOSCOPE, V92, P314
[10]   An Epistaxis Severity Score for Hereditary Hemorrhagic Telangiectasia [J].
Hoag, Jeffrey B. ;
Terry, Peter ;
Mitchell, Sally ;
Reh, Douglas ;
Merlo, Christian A. .
LARYNGOSCOPE, 2010, 120 (04) :838-843